Novo Files for Degludec and DegludecPlus Approval in Europe

Novo Nordisk has filed for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe. According to their press release Novo will also be submitting both drugs to the FDA within two weeks. Both drugs will be available with a pen delivery system.